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Abstract
Aims To evaluate the interaction effects of gestational diabetes (GDM) with obesity on perinatal outcomes.
Methods A population-based cohort study in Sweden excluding women without pre-gestational diabetes with a
singleton birth between 1998 and 2012. Logistic regression was performed to evaluate the potential independent
associations of GDM and BMI with adverse perinatal outcomes as well as their interactions. Main outcome measures
were malformations, stillbirths, perinatal mortality, low Apgar score, fetal distress, prematurity and Erb’s palsy.
Results Some 1,294,006 women were included, with a GDM prevalence of 1% (n = 14,833). The rate of overweight/
obesity was 67.7% in the GDM-group and 36.1% in the non-GDM-group. No significant interaction existed. Offspring
of women with GDM had significantly increased risk of malformations, adjusted odds ratio (aOR) 1.16 (95% confidence
intervals 1.06–1.26), prematurity, aOR 1.86 (1.76–1. 98), low Apgar score, aOR 1.36 (1.10–1.70), fetal distress, aOR
1.09 (1.02–1.16) and Erb’s palsy aOR 2.26 (1.79–2.86). No risk for stillbirth or perinatal mortality was seen. Offspring
of overweight (BMI 25–29.9 kg/m2), obese (BMI 30–34.9 kg/m2) and severely obese women (BMI ≥ 35.0 kg/m2) had
significantly increased risks of all outcomes including stillbirth 1.51 (1.40–1.62) to 2.85 (2.52–3.22) and perinatal
mortality 1.49 (1.40–1.59) to 2.83 (2.54–3.15).
Conclusions There is no interaction effect between GDM and BMI for the studied outcomes. Higher BMI and GDM are
major independent risk factors for most serious adverse perinatal outcomes. More effective pre-pregnancy and antenatal
interventions are required to prevent serious adverse pregnancy outcomes among women with either GDM or high BMI.
Diabet. Med. 36, 151–157 (2019)
Introduction
Overweight and obesity are public health problems in many
parts of the world. In 2014, 39% of the world’s population
was overweight and 13% were obese [1]. The high preva-
lence of obesity among women of childbearing age is
unprecedented [2]. The incidence of gestational diabetes
mellitus (GDM) in Sweden has increased slowly as a
consequence of increased rates of obesity, immigration and
higher maternal age [3]. It is well known that both GDM and
overweight/obesity increase risks for maternal and fetal
complications in pregnancy, delivery and the neonatal period
[4–10]. Whether adverse outcomes are related to GDM
(hyperglycaemia) per se or to overweight/obesity (50–70% of
women with GDM are overweight/obese) is known to some
extent [11,12]. We have previously demonstrated that
normal weight women with GDM have the same increments
in risk for adverse maternal outcomes and excessive fetal
growth as overweight women without GDM [13]. However,
data on serious perinatal outcomes remain scant, and
conflicting information on risks of malformations and
perinatal mortality in offspring of women with GDM have
been presented [14,15].
Visceral fat increases insulin resistance and potentiates
development of the metabolic syndrome. This suggests that
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the combination of overweight and GDM could amplify the
risk of adverse perinatal outcomes creating a multiplicative
or additive effect [16]. Such information would be helpful in
the clinical setting to identify pregnancies at higher risk of
complications.
Our first aim was to evaluate possible interaction effects
between maternal BMI and GDM on adverse perinatal
outcomes. Second, we evaluated whether, and how, maternal
excess weight (overweight, obesity, severe obesity) and
GDM are independently associated with adverse perinatal
outcomes.
Participants and methods
The study population consisted of all women with a singleton
birth in Sweden between 1998 and 2012. Data were derived
from the Medical Birth Register (MBR) which is maintained
by the National Board of Health and Welfare. The register
contains data on > 98% of births in Sweden since 1973 [17].
Information on all hospital births is collected prospectively
and includes demographic data and diagnoses during preg-
nancy, delivery and the neonatal period, using standardized
forms. The MBR is validated regularly and the quality of the
variables included in the present investigation is high [17].
Women with pre-gestational diabetes (Type 1 and Type 2
diabetes mellitus) were excluded from this analysis. Records
with extreme values for height and weight were excluded
(weight < 35 kg or > 200 kg and height < 140 cm or > 200
cm). Maternal BMI was calculated as weight in kilograms
divided by height in metres squared. BMI categories were
defined according to the WHO classification as underweight
(BMI < 18.5 kg/m²), normal weight (18.5–24.9 kg/m²)
overweight (25.0–29.9 kg/m²), obese (30.0–34.9 kg/m²) and
severely obese (≥ 35 kg/m²). Weight was measured at the first
visit to maternity care, usually taking place in the first
trimester [18]. Height was reported by recall.
In Sweden, the main screening strategy for GDM during
the study period was based on repeated, random, capillary
blood glucose ≥ 8 mmol/l (plasma glucose ≥ 9.0 mmol/l)
and/or traditional risk factors, i.e. first-degree family history
of diabetes, previous delivery of large for gestational age
babies, GDM in an earlier pregnancy. Some regions also
included obesity as a risk factor. Diagnosis of GDM was
based on the 75-g oral glucose tolerance test (OGTT). If
elevated random, capillary blood glucose (> 9 mmol/l) was
detected in the first trimester, an OGTT was performed with
a repeat test during the second trimester. Otherwise the
OGTT was performed in gestational week 28–32. During
1998–2012, there was a shift towards performing the OGTT
in gestational week 24–28 which is in line with international
guidelines. The Swedish MBR does not have the timing of
OGTT documented. During the study period, the main
diagnostic criteria for GDM were fasting, capillary, whole-
blood glucose ≥ 6 mmol/l and/or 2-h blood glucose ≥ 9
mmol/l. In the middle of the study period, there was a switch
from measuring whole-blood glucose to plasma glucose. The
diagnostic criteria based on plasma glucose included cut-off
levels for fasting glucose of ≥ 7.0 mmol/l and for 2-h glucose
of ≥ 10.0 mmol/l. A small region in Sweden has offered a
simplified 75-g OGTT (including only the 2-h blood glucose
measurement) to all pregnant women since 1995. The
diagnostic criteria for GDM for this simplified OGTT was
2-h blood glucose ≥ 10.0 mmol/l [19]. In another region,
during 1998–2010, only women with values corresponding
to overt diabetes (fasting capillary plasma glucose ≥ 7 mmol/l
or 2-h plasma glucose ≥ 12.2 mmol/l) were diagnosed with
GDM. This region represents  20–25% of the pregnant
population.
The register does not contain data on laboratory
measures such as blood glucose. GDM and neonatal
outcomes were identified based on International Classifi-
cation of Diseases version 10 (ICD-10) codes. GDM was
identified as ICD code O24.4A or O24.4B. Chronic
hypertensive disease (CHD) was defined as hypertension
diagnosed before pregnancy or blood pressure ≥ 140/90
mmHg before week 20 of gestation (O10.0, O10.2, O10.4
and O10.9). Preterm delivery was defined as birth before
37 completed weeks of gestation. Malformations include
all ICD codes Q00–Q99. The definition of stillbirth
changed during the study period. Before 2008, stillbirth
was defined as birth of a dead fetus after 28 completed
gestational weeks. From 2008, stillbirth was defined in the
MBR as fetal death after 22 completed gestational weeks
(ICD code O36.4). Perinatal mortality included both
stillbirths and deaths during the first 7 days postpartum.
Fetal distress was defined as a reason for intervention (i.e.
Caesarean section or vacuum extraction) due to suspected
fetal hypoxia during pregnancy or delivery (ICD code
O68.9). Low Apgar score was defined as Apgar < 4 points
at 5 min of age. Erb’s palsy was identified based on ICD
code P14.0. Sensitivity analysis was done to account for
possible differences between regions and the effects of
overt diabetes during pregnancy.
What’s new?
• It is known that both gestational diabetes (GDM) and
maternal overweight are associated with adverse peri-
natal outcomes.
• Excess maternal weight and GDM have comparable
and independent effects on adverse perinatal outcomes.
• GDM is not associated with perinatal mortality and
stillbirth in the Swedish population.
• There is a need for research on interventions that reduce
the effects of hyperglycaemia and prevent/better man-
age overweight/obesity to be able to improve perinatal
outcomes.
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The study was approved by the Regional Ethical Commit-
tee in Uppsala, Sweden (2009/187/1).
Statistical analyses
To compare maternal characteristics and perinatal outcomes
between women with and without GDM the v2 test was
used, except for maternal age and BMI for which the
unpaired t-test was used. To compare maternal characteris-
tics and perinatal outcomes between BMI groups the v2 test
for trend was used for all variables, except maternal age for
which analysis of covariance was used as a trend test.
Unadjusted, logistic regression was used to compare perina-
tal outcomes in offspring in relation to mothers’ GDM and
BMI separately. Adjustment was made for GDM and BMI by
having the variables in the same model and further adjust-
ment was made for other potential confounders such as
maternal age, non-Nordic decent, parity, smoking and
chronic hypertension. Finally, in the final adjusted model,
an interaction test of GDM and BMI was assessed which
evaluates whether GDM potentiates rather than simply adds
to the effect of obesity on the risk of adverse outcomes. In the
logistic regression models, all independent variables were
entered as categorical except for maternal age which was
evaluated on a continuous scale. Logistic regression gave
odds ratios (OR) with 95% confidence intervals (95% CI) as
measure of association. A P-value < 0.05 was considered
statistically significant. All statistical analyses were per-
formed using SPSS statistical software, version 22 (IBM,
Armonk, NY, USA).
Results
After exclusion of women with Type 1 and Type 2 diabetes
before pregnancy, and women with multiple pregnancies, the
study cohort included 1,294,006 women with data on early
pregnancy BMI; 14,833 women (1%) were diagnosed with
GDM. Data on BMI were missing in 11% of the women;
however, the proportion of GDM in women without infor-
mation on BMI was the same (1%) as in women with BMI
data. For detailed characteristics of women with missing data
on BMI see Table S1. Of all studied women, 35.9% had a
BMI ≥ 25 kg/m2 and 11.3% had a BMI ≥ 30 kg/m2. Among
women with GDM, 67.7% were overweight or obese and
37.6%were obese. During the study period, the proportion of
women with GDM increased from 0.7% in 1998 to 1.2% in
2012. The proportion of non-Nordic women also increased
from 15.7% in 1998 to 24.6% in 2012. Maternal character-
istics differed between women with and without GDM
(Table 1), and between BMI groups (Table 2).
The proportion of perinatal outcomes in women with and
without GDM are presented in Table 1. There were signif-
icantly elevated risks of malformations, fetal distress, low
Apgar score, prematurity and Erb’s palsy in offspring of
women with GDM compared with offspring of women
without GDM in the unadjusted model (Table 3). The
elevated risks were present after adjusting for BMI and also
in the third model with adjustment for other potential
confounders (Table 3). There was no increased risk of
stillbirth or perinatal mortality in the offspring of women
with GDM compared with women without GDM after
taking potential confounders into account, including BMI
(Table 3). The proportion of perinatal outcomes in women
in the different BMI categories are presented in Table 2.
Elevated risks of all outcomes were significantly increased in
offspring of women that were overweight, obese and severely
obese compared with normal weight both unadjusted and
adjusted for all potential confounders (Table 3). Risks
increased with increasing BMI. The risk increase due to
BMI was most pronounced when analysing perinatal death,
stillbirth and Erb’s palsy, especially for women with a BMI
> 30 kg/m2. Including only pregnancies beyond 37 weeks
(i.e. term pregnancies) did not alter the results (data not
shown). In the adjusted model there was no significant
interaction between GDM and BMI for any of the studied
outcomes (Table 3).
Sensitivity analysis excluding the region in Sweden diag-
nosing GDM on values corresponding to overt diabetes did
not change the results for any studied outcome (data not
shown). All analyses were repeated with BMI on a contin-
uous scale and this also did not change the results.
Discussion
In this large, population-based cohort study in Sweden, we
show that, besides for prematurity, the impact of maternal,
Table 1 Maternal characteristics and perinatal outcomes according to
the presence of gestational diabetes (GDM)
No GDM
(n = 1 440 834)
GDM
(n = 14 833) P-value*
Maternal characteristics
BMI 24.5  4.4 28.7  6.3 < 0.01
Age(years) 30  5.2 32  5.4 < 0.01
Non-Nordic 275 592 (18.8) 5914 (39.3) < 0.01
Primiparous 641 360 (44.4) 5299 (35.7) < 0.01
Chronic
hypertension
4274 (0.3) 196 (3.1) < 0.01
Smoking 117 764 (8.4) 1339 (9.2) < 0.01
Perinatal outcomes
Malformation 49 938 (3.5) 611 (4.1) < 0.01
Perinatal
mortality
6506 (0.5) 70 (0.5) 0.69
Stillbirth 4852 (0.3) 58 (0.4) 0.26
Prematurity 70 892 (4.9) 1405 (9.5) < 0.01
Apgar < 4
at 5 mi
4939 (0.3) 94 (0.6) < 0.01
Fetal distress 98 360 (6.8) 1196 (8.1) < 0.01
Erb’s palsy 2526 (0.2) 85 (0.6) < 0.01
Data are presented as n (%) or mean  SD.
*Unpaired t-test was used to analyse BMI and age, the v2-test
was used for all other maternal characteristics and outcomes.
Missing data for BMI was 11%.
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excess weight on adverse perinatal outcomes did not differ
significantly between the offspring of mothers with and
without GDM. Maternal overweight and obesity and GDM
are major, independent risk factors for most adverse perina-
tal outcomes. Offspring of women with GDM had increased
risk of malformations, prematurity, fetal distress and Erb’s
palsy, but the risks of stillbirth and perinatal mortality were
comparable with the risks in the reference population. This
was despite being diagnosed with higher glycaemic thresh-
olds than the current WHO criteria [20]. Overweight,
obesity and severe obesity were independent risk factors for
malformations, stillbirths, perinatal mortality, low Apgar
score at 5 min and Erb’s palsy. Of concern is that even the
offspring of women who were only in the overweight BMI
category had significantly increased risks of stillbirth and
perinatal mortality. This large group of women (BMI 25–
29.9 kg/m2) does not usually receive any special antenatal
care despite the increased risks.
The strength of this study is that it is a nationwide registry-
based study, in which data are collected from medical
records. BMI is based on weight measured by the midwife,
not self-reported. Data on BMI was missing in 11% of the
women, but rate of GDM did not differ significantly between
women with and without information on BMI. Because of
the large study population, we were able to analyse interac-
tion effects and the risks of less common outcomes such as
mortality and malformations.
A limitation is that there are no laboratory data from the
OGTTs or measures of glycaemia during pregnancy. In
Sweden, the screening strategies for GDM have also varied
over the years, and the effects of these differences are difficult
to evaluate. Because Swedish GDM criteria have been high by
international standards, many women that elsewhere would
have been diagnosed with GDM were considered ‘normal’ in
this study. This might have resulted in an underestimation of
the differences between the groups. It is possible that the
study cohort included a few women with Type 2 diabetes
detected for the first time during pregnancy. However, the
rate of Type 2 diabetes in pregnant women in Sweden is very
low [3]. TheMBR does not include data on induced abortions
due to malformations, which allowed us to study only
malformations in pregnancies after 22 gestational weeks.
This study shows that there is no interaction effect between
BMI and GDM status for the studied outcomes. This is the
first study on the interaction effects between GDM and
maternal weight on perinatal outcomes.
We also confirm that overweight and obesity are associ-
ated with increased rates of severe adverse perinatal out-
comes independent of GDM. The same independent
association has been reported for maternal outcomes and
large for gestational age [11,13].
Hyperglycaemia in early pregnancy is associated with an
increased risk of major malformations [21–23]. The observed
increased risks of major malformations in offspring of
women with GDM were still low, and most likely due to
undiagnosed cases of Type 2 diabetes. Overweight/obesity
were independent risk factors of malformations, but the
absolute risk increase was small. Feig et al. [24] also found
increased risk of congenital malformations among offspring
of women with GDM, but wondered if this was due to
overweight and obesity.
Obese women have an increased risk for both stillbirth and
perinatal mortality [25,26]. In this study, we found no
significant independent effect of GDM after adjusting for
potential confounding factors including BMI. There are few
large studies with data on rates of perinatal mortality and
Table 2 Maternal characteristics and perinatal outcomes according to BMI
BMI (kg/m2)
< 18.5
(n = 31 041)
18.5–24.9
(n = 794 342)
25–29.9
(n = 322 391)
30–34.9
(n = 103 942)
> 34.9
(n = 42 290) P-value*
Maternal characteristics
GDM 151 (0.5) 4114 (0.5) 3972 (1.2) 2786 (2.7) 2185 (5.2) < 0.01
Age (years) 27.7  5.3 29.9  5.1 30.4  5.2 30.3  5.4 30.2  5.3 < 0.01
Non-Nordic 9202 (29.6) 141 082 (17.8) 66 944 (29.8) 21 756 (20.9) 7114 (16.8) < 0.01
Primiparous 16 798 (54.1) 375 798 (47.3) 128 140 (39.7) 37 671 (36.2) 15 033 (35.5) < 0.01
Chronic hypertension 33 (0.1) 1310 (0.2) 1225 (0.4) 819 (0.8) 550 (1.3) < 0.01
Smoking 3606 (11.6) 57 754 (7.3) 29 223 (9.1) 12 249 (11.8) 5838 (13.8) < 0.01
Perinatal outcomes
Malformation 1055 (3.4) 27 110 (3.4) 11 281 (3.5) 3752 (3.6) 1633 (3.9) < 0.01
Perinatal mortality 91 (0.3) 2598 (0.3) 1591 (0.5) 691 (0.7) 394 (0.9) < 0.01
Stillbirth 69 (0.2) 1945 (0.2) 1208 (0.4) 534 (0.5) 298 (0.7) < 0.01
Prematurity 1916 (6.2) 35 542 (4.5) 15 368 (4.8) 5700 5.5) 2843 (6.7) < 0.01
Apgar < 4 at 5 min 66 (0.2) 2124 (0.3) 1242 (0.4) 495 (0.5) 315 (0.7) < 0.01
Fetal distress 2005 (6.5) 52 853 (6.7) 22 516 (7.0) 7804 (7.5) 3395 (8.0) < 0.01
Erb’s palsy 20 (0.1) 1025 (0.1) 727 (0.2) 343 (0.3) 191 (0.5) < 0.01
Data are presented as n (%) or mean  SD.
*Trend test of covariance was used to analyse age. A v2-test for trend was used for all other maternal characteristics and outcomes. Missing
data for BMI was 11%.
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Table 3 Gestational diabetes (GDM) and BMI associations on perinatal outcomes analysed with logistic regression
Unadjusted
Adjusted for
GDM/BMI*
Adjusted for all
possible confounders†
P-valueOR (95% CI) OR (95% CI) OR (95% CI)
Malformations
GDM 1.20 (1.10–1.30) 1.15 (1.06–1.26) 1.16 (1.06–1.26)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
< 18.5 1.00 (0.94–1.06) 1.0 (0.94–1.06) 1.02 (0.95–1.08)
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25–29.9 1.03 (1.00–1.05) 1.03 (1.00–1.05) 1.04 (1.01–1.06)
30–34.9 1.06 (1.02–1.10) 1.06 (1.02–1.09) 1.08 (1.04–1.11)
≥ 35.0 1.14 (1.08–1.20) 1.13 (1.07–1.19) 1.15 (1.09–1.21)
Interaction test 0.56
Perinatal mortality
GDM 1.05 (0.83–1.32) 0.90 (0.70–1.14) 0.79 (0.62–1.01)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
< 18.5 0.90 (0.73–1.11) 0.90 (0.73–1.11) 0.89 (0.72–1.09)
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25–29.9 1.51 (1.42–1.61) 1.51 (1.42–1.61) 1.49 (1.40–1.59)
30–34.9 2.04 (1.88–2.22) 2.04 (1.88–2.22) 2.01 (1.85–2.19)
≥ 35.0 2.87 (2.58–3.19) 2.88 (2.59–3.21) 2.84 (2.55–3.17)
Interaction test 0.86
Stillbirth
GDM 1.16 (0.90–1.51) 1.0 (0.77–1.31) 0.87 (0.66–1.13)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
< 18.5 0.91 (0.71–1.15) 0.91 (0.71–1.15) 0.90 (0.70–1.14)
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25–29.9 1.53 (1.43–1.65) 1.53 (1.43–1.65) 1.51 (1.40–1.62)
30–34.9 2.10 (1.91–2.32) 2.10 (1.91–2.32) 2.06 (1.87–2.27)
≥ 35.0 2.89 (2.56–3.27) 2.89 (2.56–3.27) 2.85 (2.52–3.22)
Interaction test 0.38
Prematurity
GDM 2.02 (1.91–2.14) 1.91 (1.80–2.03) 1.87 (1.76–1.98)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
< 18.5 1.40 (1.34–1.47) 1.41 (1.34–1.47) 1.37 (1.31–1.44)
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25–29.9 1.07 (1.05–1.09) 1.06 (1.04–1.08) 1.08 (1.06–1.10)
30–34.9 1.24 (1.20–1.28) 1.22 (1.18–1.25) 1.24 (1.20–1.27)
≥ 35.0 1.54 (1.48–1.60) 1.48 (1.42–1.54) 1.49 (1.43–1.55)
Interaction test 0.30
Apgar < 4 at 5 min of age
GDM 1.85 (1.51–2.26) 1.54 (1.24–1.91) 1.36 (1.10–1.70)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
< 18.5 0.80 (0.62–1.02) 0.80 (0.62–1.02) 0.78 (0.61–1.00)
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25–29.9 1.44 (1.35–1.55) 1.44 (1.34–1.54) 1.45 (1.35–1.56)
30–34.9 1.79 (1.62–1.97) 1.76 (1.60–1.95) 1.80 (1.63–1.98)
≥ 35.0 2.80 (2.49–3.15) 2.73 (2.42–3.08) 2.81 (2.49–3.17)
Interaction test 0.38
Fetal distress
GDM 1.20 (1.13–1.27) 1.15 (1.08–1.22) 1.09 (1.02–1.16)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
< 18.5 0.97 (0.93–1.01) 0.97 (0.93–1.02) 0.96 (0.92–1.01)
18.5–24.9 1 (reference) 1 (reference) 1 (reference)
25–29.9 1.05 (1.04–1.07) 1.05 (1.04–1.07) 1.14 (1.12–1.15)
30–34.9 1.14 (1.11–1.17) 1.14 (1.11–1.16) 1.29 (1.26–1.32)
≥ 35.0 1.23 (1.18–1.27) 1.22 (1.17–1.26) 1.40 (1.35–1.46)
Interaction test 0.16
Erb’s palsy
GDM 3.28 (2.64–4.08) 2.36 (1.87–2.98) 2.26 (1.79–2.86)
No GDM 1 (reference) 1 (reference) 1 (reference)
BMI groups (kg/m2)
ª 2018 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 155
Research article DIABETICMedicine
stillbirth in women with GDM. Billionnet et al. [14] showed
an increased risk for perinatal mortality for women with
GDM after 37 weeks; however, they were not able to adjust
for maternal BMI in their analyses. Feig et al. [24] reported
decreased risks of perinatal mortality in women with GDM
compared with pregnancies without diabetes. They argue that
this might be due to more intense management in pregnancies
of women with GDM. This is in contrast to the findings in our
study, which is more in line with the results of Ovesen et al.
[27]. The finding is interesting because women with GDM in
this study were diagnosed using higher cut-off values for
plasma glucose than the International Association of Diabetes
in Pregnancy Study Group (IADPSG) criteria [28].
There are few studies reporting risks of fetal distress and
low Apgar scores in offspring of pregnancies in women with
GDM. Ovesen et al. [27] found no significant differences in
Apgar score < 7 at 5 min in offspring of women with or
without GDM. In the ACHOIS study, a randomized
controlled trial of women with GDM receiving active
treatment (dietary advice, blood glucose monitoring and
insulin therapy) or routine care, there was no difference in
risk of low Apgar score between the offspring of mothers in
the routine care and the intervention groups [29]. In the
current study, we used Apgar < 4 at 5 min because it is a
strong predictor of neonatal complications [30]. We found a
slightly elevated risk of low Apgar scores in offspring of
women with GDM compared with women without GDM.
Offspring of mothers with GDM also had a slightly elevated
risk of fetal distress, and in offspring of mothers without
GDM risks increased with maternal BMI. This is in contrast
to the finding of a markedly increased risk of fetal distress in
offspring of mothers with Type 1 diabetes [31].
The risk of Erb’s palsy has been studied previously with
contradictory results. There are studies reporting no
increased risks of Erb’s palsy in offspring of women with
GDM [32,33]. In a previous Swedish study, the risk of Erb’s
palsy was more than doubled in offspring of women with
GDM, even after taking maternal BMI into account [34]. We
confirm these results and also show that overweight/obesity
had a similar impact on the relative risk of Erb’s palsy as
GDM. Because we have shown that there was no interaction,
the risks of Erb’s palsy associated with overweight/obesity
are additional to the risk conveyed by GDM.
We also repeated all calculations including only women
with a term pregnancy (> 37 weeks) because that is the vast
majority of women seen in the clinics. This did not change
the conclusions.
The rate of GDM in Sweden is low due to screening
policies, strict diagnostic criteria and generally, a low
background prevalence of Type 2 diabetes. Whether a more
extensive GDM screening programme and a more stringent
treatment regimen would reduce the risks of neonatal
morbidity need to be further studied and explored. Further
research is also needed into pre-pregnancy and antenatal
interventions that will reduce the risk of adverse neonatal
outcomes among overweight and obese women [35,36].
Improvements in uncommon, but serious outcomes such as
stillbirth and perinatal mortality need research into inter-
ventions that both reduce the effects of hyperglycaemia and
prevent/better manage overweight/obesity.
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Table 3 (Continued)
Unadjusted
Adjusted for
GDM/BMI*
Adjusted for all
possible confounders†
P-valueOR (95% CI) OR (95% CI) OR (95% CI)
< 18.5 0.50 (0.32-0.78) 0.50 (0.32-0.78) 0.49 (0.32-0.76)
18.5–24.9 1 (reference) 1(reference) 1(reference)
25–29.9 1.75 (1.59–1.92) 1.73 (1.58–1.91) 1.72 (1.56–1.89)
30–34.9 2.56 (2.27–2.90) 2.49 (2.20–2.82) 2.48 (2.20–2.81)
≥ 35.0 3.55 (3.01–4.10) 3.31 (2.83–3.87) 3.37 (2.98–3.95)
Interaction test 0.69
OR, odds ratio; CI, confidence interval
*With GDM and BMI in the same model adjusted for each other.
†With GDM and BMI in the same model adjusted for each other and for maternal age, non-Nordic origin, parity, smoking and chronic
hypertension.
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